ViGenCell Inc
308080
Company Profile
Business description
ViGenCell Inc specializes in immune cell therapy products. The companies various immune cell therapies has contributed to prolonged life expectancy and much enhanced quality of life for patients suffering from incurable diseases.
Contact
222 Banpo-daero
7th floor, Seoul St. Mary's Hospital Annex
Seocho-gu
Seoul06591
KORT: +82 234781685
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
63
Stocks News & Analysis
stocks
Is this still an ASX share to own forever?
Find out how this defensive player has fared after earnings.
stocks
After earnings, is Nvidia stock a buy, a sell, or fairly valued?
No signs of a slowdown in demand for Nvidia’s chips, and the long-term picture looks bright.
stocks
Short-term pain for long-term gain for undervalued ASX share
Cost reductions lower our profit estimates but should lead to improved long-term outcomes.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,131.20 | 1.70 | 0.02% |
| CAC 40 | 7,698.92 | 20.79 | -0.27% |
| DAX 40 | 23,770.33 | 175.53 | 0.74% |
| Dow JONES (US) | 45,621.29 | 350.06 | 0.77% |
| FTSE 100 | 9,216.87 | 38.88 | 0.42% |
| HKSE | 25,165.29 | 106.78 | 0.43% |
| NASDAQ | 21,707.69 | 209.97 | 0.98% |
| Nikkei 225 | 42,915.45 | 335.18 | 0.79% |
| NZX 50 Index | 13,207.66 | 74.46 | 0.57% |
| S&P 500 | 6,502.08 | 53.82 | 0.83% |
| S&P/ASX 200 | 8,863.20 | 0.60 | 0.01% |
| SSE Composite Index | 3,763.11 | 2.76 | -0.07% |